T-cell engagers (TCEs) are transforming cancer immunotherapy, but their unique mechanisms—such as dual-targeting specificity and complex immune modulation—demand innovative preclinical evaluation approaches to ensure successful clinical translation. Traditional preclinical models often struggle to mimic the complexity of human immune responses, leading to gaps in predicting efficacy and safety. 

This webinar will cover the in vitro and in vivo approaches that can bridge these gaps as well as strategies to address translational risks in TCE development.

In this webinar, we will be: 

• Navigating progress and challenges in TCE development

• Introducing next-generation models such as PBMC-NCG, PBMC-NCG-MHC-DKO and huHSC-NCG

• Discussing innovative safety assessment strategies using CD3EDG humanized systems and HSC-reconstituted models

• Presenting integrated in vitro and in vivo preclinical evaluation solutions for TCEs

Time: 

Wednesday, June 18, 2025

2:00 PM CST | 3:00 PM KST | 3:00 PM JST